Fundraising FoxImmutep
1 known investors
Find your way into Immutep
Sign up to see every warm intro you have to Immutep
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immutep team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immutep is a late clinical-stage biotechnology company developing immunotherapies targeting the LAG-3 (Lymphocyte Activation Gene-3) immune molecule to treat cancer and autoimmune diseases. Its product portfolio uses LAG-3 to either stimulate the immune response against cancer or modulate it to address autoimmune conditions.
Investors · 1
Frequently asked questions
- What does Immutep do?
- Immutep is a late clinical-stage biotechnology company developing immunotherapies targeting the LAG-3 (Lymphocyte Activation Gene-3) immune molecule to treat cancer and autoimmune diseases. Its product portfolio uses LAG-3 to either stimulate the immune response against cancer or modulate it to address autoimmune conditions.
- Who are Immutep's investors?
- Immutep's investors include Ridgeback Capital.